These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38854928)

  • 61. Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology.
    Setnik B; Schoedel KA; Levy-Cooperman N; Shram M; Pixton GC; Roland CL
    J Opioid Manag; 2017; 13(6):485-523. PubMed ID: 29308594
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
    Keast SL; Owora A; Nesser N; Farmer K
    J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.
    Walter C; Knothe C; Lötsch J
    Clin Pharmacokinet; 2016 Jul; 55(7):751-767. PubMed ID: 26719075
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.
    Webster LR; Pantaleon C; Shah MS; DiFalco R; Iverson M; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2017 Jul; 18(7):1303-1313. PubMed ID: 27651506
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessment of extended-release opioid analgesics for the treatment of chronic pain.
    Gudin JA
    J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):49-61. PubMed ID: 23527669
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oxycodone DETERx
    Lamb YN; Garnock-Jones KP; Keam SJ
    Drugs; 2016 Dec; 76(18):1759-1769. PubMed ID: 27832472
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
    Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
    J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.
    McCarberg BH; Kopecky EA; O'Connor M; Marseilles A; Varanasi RK; Thompson C; Fleming AB
    Curr Med Res Opin; 2016 Dec; 32(12):1975-1982. PubMed ID: 27668546
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Kucera SA; Zamloot MS; Crowley MM; Burns LH; Friedmann N; Barbier R
    J Opioid Manag; 2018; 14(6):429-436. PubMed ID: 30629279
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and performance of current abuse-deterrent formulations.
    Ahmad R; Alaei S; Omidian H
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1255-1271. PubMed ID: 30408424
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?
    Schneider JP; Matthews M; Jamison RN
    CNS Drugs; 2010 Oct; 24(10):805-10. PubMed ID: 20839893
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oxycodone extended release capsules for the treatment of chronic pain.
    Mercadante S
    Expert Rev Neurother; 2017 May; 17(5):427-431. PubMed ID: 28277802
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
    Webster L
    Pain Med; 2009 Jul; 10 Suppl 2():S124-33. PubMed ID: 19691683
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 77. NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.
    Miyazaki T; Choi IY; Rubas W; Anand NK; Ali C; Evans J; Gursahani H; Hennessy M; Kim G; McWeeney D; Pfeiffer J; Quach P; Gauvin D; Riley TA; Riggs JA; Gogas K; Zalevsky J; Doberstein SK
    J Pharmacol Exp Ther; 2017 Oct; 363(1):104-113. PubMed ID: 28778859
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance.
    Zhao L; Li Z; Fang L; Kim MJ; Nallani SC; Sahajwalla CG; Calderon SN; Roca RA; Feng K; Zineh I; Lionberger R
    EClinicalMedicine; 2021 Nov; 41():101135. PubMed ID: 34585126
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The implications of tamper-resistant formulations for opioid rotation.
    Pappagallo M; Sokolowska M
    Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
    Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
    Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.